Cyfuse Biomedical K.K.

4892.T
Drug Manufacturers - Specialty & Generic
2026/11/20 20:23 Updated
Market Cap: $31.0M (¥4.9B)
Stock Price: $3.07 (¥487)
Exchange Rate: 1 USD = ¥158.73

Notice Regarding Progress in Development of New 3D Cellular Products and Recognition of Non-Operating Income

Upon completion of the publicly funded project, 15,000 thousand yen will be recognized as non-operating income. Going forward, the Company will promote practical application and commercialization of FCD products and aim to expand offerings including 3D mini-intestinal models.

Importance:
Page Updated: November 19, 2026
IR Disclosure Date: November 19, 2026

Key Figures

  • Amount of non-operating income recognized: Unknown (not stated in the text)
  • Grant amount: 15,000 thousand yen
  • Date confirmation notice received: Unknown

AI要約

Overview and Outcomes of the Project

This project was conducted as part of the Tokyo Metropolitan Small and Medium Enterprise Support Center public solicitation program "FY2024 New Product/New Technology Development Subsidy Program" and advanced development of FCD products with the objective of enhancing drug efficacy evaluation for organ fibrosis diseases through the development of a three-dimensional extracellular matrix (3D extracellular matrix). We report completion of the project and establishment of the associated technologies and knowledge.

Future Outlook and Business Strategy

We are already selling a human 3D mini-liver model that reproduces liver fibrosis and are expanding its use in drug discovery research. Going forward, we will pursue practical application and commercialization of FCD products and promote expansion of the product lineup combining human 3D mini-liver (healthy and disease models) with 3D mini-intestinal models. We also indicate potential applications of the extracellular matrix in oncology for drug efficacy evaluation and novel therapeutic development.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Cyfuse Biomedical K.K.

Company overview · Stock price · Financial data · All IR

View company page →